CTNM — Contineum Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1855175 ·
Last close
$9.55
Market Cap
$337.62M
52W High
$17.78
52W Low
$6.72
ADV30
1,012,020
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -20,966,000 -18,697,000 256,988,000 75,198,000 11,570,000
Jun 2026 0 — -17,428,000 -15,154,000 250,367,000 14,711,000 10,707,000
Mar 2026 0 — -16,904,000 -14,456,000 261,349,000 20,158,000 11,308,000
Dec 2025 0 — -17,115,000 -15,156,000 276,642,000 75,603,000 15,653,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-51,869,000
Investing CF
$-30,954,000
Financing CF
$115,388,000
CapEx
$-458,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.77
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-225,687,000
Inventory
—
Receivables
—
ST Investments
$169,286,000
EBIT TTM
$-72,413,000
Pretax Income TTM
$-63,463,000
Interest Exp TTM
—
Analysts
7

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -68,059,000 -59,978,000 276,642,000 15,653,000 260,989,000 -55,312,000
Dec 2024 0 -50,894,000 -42,258,000 212,847,000 14,781,000 198,066,000 -32,845,000
Dec 2023 50,000,000 16,077,000 22,720,000 130,386,000 198,322,000 -67,936,000 19,349,000
Dec 2022 0 -22,720,000 -24,253,000 50,636,000 143,848,000 -93,212,000 -20,121,000

TTM Snapshot

Revenues TTM
$8,814,000
NetIncome TTM
$-57,558,000
OpCashFlow TTM
—
Assets (Latest)
$250,367,000
Forward EPS
$-1.99

Max Pain — expiry 2026-12-18

max pain strike: $15.00 · spot: $9.24 · call oi: 5,068 · put oi: 288
Expected Move to 2026-12-18: ±$2.38 (25.70%) — implied range $6.87 – $11.62 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LYEL Lyell Immunopharma, Inc. $336.08M $13.67 —
VREOF Vireo Growth Inc. $346.76M $6.01 —
ASPE Aspen Neuroscience, Inc. $348.94M $12.00 —
RLMD RELMADA THERAPEUTICS, INC. $321.15M $3.01 —
AVIR Atea Pharmaceuticals, Inc. $318.00M $3.96 —

News headlines (Yahoo Finance, 1h cache)

Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
2026-11-09 09:35 · Yahoo
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
2026-11-03 21:05 · Yahoo
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
2026-10-29 20:05 · Yahoo
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
2026-10-12 15:00 · Yahoo
Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results
2026-10-12 12:42 · Yahoo
Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating
2026-10-12 11:55 · Yahoo
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
2026-09-24 23:04 · Yahoo
Sector Update: Healthcare Stocks Ease Late Afternoon
2026-09-15 19:52 · Yahoo
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
2026-09-14 21:32 · Yahoo
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
2026-08-25 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.